Nicotinamide (NSC 13128)

For research use only. Not for use in humans.

目录号:S1899 别名: Niacinamide, Vitamin PP, Nicotinic acid amide, Vitamin B3, NSC 27452 中文名称:烟酰胺(维生素B3)

Nicotinamide (NSC 13128) Chemical Structure

CAS No. 98-92-0

Nicotinamide (NSC 13128, Niacinamide, Vitamin PP, Nicotinic acid amide, Vitamin B3, NSC 27452)是一种水溶性维生素,是NAD 和 NADP的活性成分,也是一种sirtuins抑制剂。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1061.88 现货
RMB 781.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Nicotinamide (NSC 13128)发表文献24篇:

产品安全说明书

Sirtuin抑制剂选择性比较

生物活性

产品描述 Nicotinamide (NSC 13128, Niacinamide, Vitamin PP, Nicotinic acid amide, Vitamin B3, NSC 27452)是一种水溶性维生素,是NAD 和 NADP的活性成分,也是一种sirtuins抑制剂。
靶点
Sirtuin [1]
体外研究

Nicotinamide强烈抑制酵母(SIR2突变)沉默,增加的rDNA重组,并缩短复制寿命。Nicotinamide废除沉默,导停滞致在G1期的细胞中Sir2离域,这表明沉默的异染色质需要不断的Sir2的活性。[1] Nicotinamide导致胎儿细胞中DNA含量增加2倍,胰岛素含量增加3倍。Nicotinamide诱导人胎儿胰岛细胞的分化和成熟。[2] Nicotinamide通过转换去乙酰化和基团交换来调节乙酰化酶。Nicotinamide切换定量为Sir2s从Archeaglobus fulgidus(Sir2Af2),酿酒酵母(Sir2p)和小鼠(Sir2alpha)。[3] Nicotinamide选择性降低的特定磷酸化tau蛋白(Thr231),和阿尔茨海默氏病的转基因小鼠的微管解聚有关,类似于对SIRT1的抑制。在阿尔茨海默氏病的转基因小鼠中,Nicotinamide也极大地增加了乙酰化的α-微管蛋白(SIRT2的一级底物)和MAP2c,这两者都与增加的微管的稳定性有关。[4] Nicotinamide促进DNA的完整性,并保持磷脂膜不对称性,以防止细胞炎症,细胞吞噬功能和血管栓塞。Nicotinamide既防止也逆转神经和血管细胞的损伤。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BL21 (DE3) MmT2SpVv[3Srb36gZZN{[Xl? NHX2[2lKdmirYnn0bY9vKG:oIHPheIFtgXSrY3HscJkh[WO2aY\lJIh2dWGwIGPJVnQ{KChzMEKgeI8hOzl7IHHtbY5wKGGlaXTzLUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KHW|aX7nJIZtfW:{b3flcolkKDdvYX3pco8uPC2vZYTofYxkd3WvYYLpckApSU2FKT3sZYJmdGWmIIDldJRq\GViYomg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyPU[uNu69VS5? NYThbJNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|U5OjRpPkK1Nlc2QDJ2PD;hQi=>
BL21 (DE3) M1L4emZ2dmO2aX;uJIF{e2G7 M3PGS2lvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5iU1nSWFIh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUApTEV|KTDj[YxteyC3c3nu[{BndHWxcn;n[Y5q[yB5LXHtbY5wNTRvbXX0bJlt[2:3bXHybY4hMEGPQzmtcIFj\WynZDDw[ZB1cWSnIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2xNE42|ryPLh?= NXn2TVhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|U5OjRpPkK1Nlc2QDJ2PD;hQi=>
BL21(DE3) NILBSmNHfW6ldHnvckBie3OjeR?= MkjwTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDTZ4hqe3Sxc3;tZUBu[W6|b37pJJNqenS3aX6gNkApOjFidH:gN|IzKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC|dXLzeJJifGViZHXhZ4V1gWyjdHnvckB2e2mwZzDaUWFNKGG|IIP1ZpN1emG2ZTygTWM2OD1{Mz6x{txONg>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTR7NkK1NUc,OzF2OU[yOVE9N2F-
SK-MEL-28 NITac|NHfW6ldHnvckBie3OjeR?= M4Lwe|ExOCC3TR?= NWfrcpdUOjRiaILz M2P2fHJm\HWldHnvckBqdiCDVGCgcIV3\WxiaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG2IEGwNEB2VSCvYXnueIFqdmWmIHnuJGxw[2unJ4Ogd49tfXSrb36gZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WtZoF{\WRiYYPzZZkhcW5iYXLz[Y5k\SCxZjDHSkBidmRiZ3z1Z49{\Q>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh|NUexPUc,OjJ6M{W3NVk9N2F-
A673 MUHxTHRUKGG|c3H5 M4DhdZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq NFH3bG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NYK5WZpOeUiWUzDhd5NigQ>? M1;2T5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN? MnfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 MYnxTHRUKGG|c3H5 M2jy[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN? MmXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 MmjKdWhVWyCjc4PhfS=> NFi5XodyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{ NIXINWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BL21(DE3) NH\G[5NHfW6ldHnvckBie3OjeR?= NYLMPFJjUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBU[2irc4Tvd49u[SCvYX7zc45qKHOrcoT1bY4hOiBqMkGgeI8hOzJ{IILld4llfWW|KTDlfJBz\XO|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzKFTFN{kh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiWl3BUC=> NFPKbW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUS5OlI2OSd-M{G0PVYzPTF:L3G+
BL21(DE3) MULGeY5kfGmxbjDhd5NigQ>? NF;hOFJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JHNkcGm|dH;zc41iKG2jboPvcokhe2m{dIXpckAzKCh{MTD0c{A{OjJicnXzbYR2\XNrIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFqRFWzLUBk\WyuczDpckBxemW|ZX7j[UBw\iBqWjmtLGJ2fCmOeYOtRW1E NGLqZpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUS5OlI2OSd-M{G0PVYzPTF:L3G+
BL21(DE3) NWDTZYQ1TnWwY4Tpc44h[XO|YYm= NXzDZWpGUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBU[2irc4Tvd49u[SCvYX7zc45qKHOrcoT1bY4hOiBqMkGgeI8hOzJ{IILld4llfWW|KTDlfJBz\XO|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzKFTFN{kh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiKGqpMUhJ\XhrTInzMWFOSw>? NH22Xpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUS5OlI2OSd-M{G0PVYzPTF:L3G+
BL21(DE3) NIPlcXVHfW6ldHnvckBie3OjeR?= MkDoTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDTZ4hqe3Sxc3;tZUBu[W6|b37pJJNqenS3aX6gNkApOjFidH:gN|IzKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmgZ4VtdHNiaX6gdJJme2WwY3Wgc4YhMFprLTjPZ5QqVHm|LVHNRy=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTR7NkK1NUc,OzF2OU[yOVE9N2F-
HEK293T NYP2WohCTnWwY4Tpc44h[XO|YYm= M3jqUVYxKG2rboO= NH7WbpBKdmirYnn0bY9vKG:oIGP0doVxXGGpLYTh[4dm\CCqdX3hckBUSVKPMTDUTXIhMDV4MTD0c{A4OjRicnXzbYR2\XNrIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCQQVThd4Uh[WO2aY\peJkhcW5icILld4Vv[2Vib3[gUmFFMyCrbnP1ZoF1\WRiZn;yJFYxKG2rboOgZpkhUFCOQzDhcoFtgXOrczygTWM2OD12Mz64{txONg>? NIPHfWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTRyLze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-MLC / MLC / p-MYPT1 / MYPT1 ; 

PubMed: 30503259     


Dose-dependent effect of nicotinamide on the phosphorylation of MYPT1 (Thr 696) and MLC (Ser 19). Individualized hESCs were treated with nicotinamide at indicated concentrations for 1 hr. Top, western blot image. Bottom, quantification of the western blot results (n = 3).

p-β-catenin / β-catenin ; 

PubMed: 30503259     


The phosphorylation of β-catenin was decreased by 10 mM nicotinamide or 5 μM CK1 inhibitor D4476 treatment for 6 hr (n = 3) as shown by western blot.

Sp1 / ERK ; 

PubMed: 18446063     


Cells were either mock-treated or treated with nicotinamide at the concentration either of 10 or 20 mM, collected at the indicated time points, and applied to Western blotting analysis.

30503259 18446063
Immunofluorescence
p-MLC; 

PubMed: 30503259     


Confocal images of individualized hESCs treated with 10 mM nicotinamide (Nam) or 10 μM ROCK inhibitor Y27632 (ROCKi). Red, phalloidin 594; green, p-MLC (Ser19). Scale bar, 10 μm.

30503259
体内研究 在小鼠中,通过腹腔注射,注射100-500 mg/kg的nicotinamide到体内将产生双相消除,其半衰期随着剂量的变化而变化。初始半衰期将显著增加,从0.8递增至2h;而终末半衰期从3.4增至5.6 h。而其在体内的消除率则只在最高浓度下发生显著减少,从0.3 L/kg/h减少至0.24 L/kg/h。体内峰值浓度也随着给药剂量发生增加,变化范围为1000-4800 nmol/ml。通过腹腔注射的药物生物利用度与静脉注射相比,接近100%[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[7]

- 合并
  • Cell lines: HaCaT细胞
  • Concentrations: 33 μM
  • Incubation Time: 7天和14天
  • Method:

    将HaCaT细胞于含10%FBS的DMEM培养基中,置于在37℃、5% CO2培养箱中培养。对于NAD(P)调节实验,将细胞培养于含10%透析FBS的DMEM培养基中,加入33 μM nicotinamide或不加入。7天或14天后,统计细胞数目,用0.1 μM 6-diazo-5-oxo-L-norleucine (DON)检测细胞对谷酰胺酶抑制的敏感性。


    (Only for Reference)
动物实验:

[6]

- 合并
  • Animal Models: 小鼠 (strain CBA/Ht/GyfBSVS)
  • Dosages: 100, 200, 300 和 500 mg/kg
  • Administration: i.p.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 24 mg/mL (196.52 mM)
Water 24 mg/mL (196.52 mM)
Ethanol '24 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 122.12
化学式

C6H6N2O

CAS号 98-92-0
储存条件 粉状
溶于溶剂
别名 Niacinamide, Vitamin PP, Nicotinic acid amide, Vitamin B3, NSC 27452

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04763499 Not yet recruiting Other: freeze dried strawberry powder Vascular Dilation University of California Davis January 1 2022 Not Applicable
NCT05040321 Not yet recruiting Drug: MIB-626|Drug: Placebo Alzheimer''s Disease (Incl Subtypes)|Dementia Brigham and Women''s Hospital December 1 2021 Phase 1|Phase 2
NCT04641663 Enrolling by invitation Dietary Supplement: Multi-target Dietary Supplement (MTDS) Aging|Age-related Cognitive Decline Douglas Boreham|McMaster University|Northern Ontario School of Medicine September 3 2021 Not Applicable
NCT04844528 Suspended Drug: Nicotinamide|Drug: Placebo Chronic Lymphocytic Leukemia University of Utah August 5 2021 Phase 2
NCT04909489 Recruiting Other: cross-sectional study without intervention Traditional Chinese Medicine|Dyslipidemias|Syndrome Dongzhimen Hospital Beijing April 21 2021 --
NCT04342975 Recruiting Drug: Nicotinamide Riboside + Pterostilbene|Drug: Placebo AKI Mayo Clinic|Elysium Health December 1 2020 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

Sirtuin Signaling Pathway Map

相关Sirtuin产品

Tags: 购买Nicotinamide (NSC 13128) | Nicotinamide (NSC 13128)供应商 | 采购Nicotinamide (NSC 13128) | Nicotinamide (NSC 13128)价格 | Nicotinamide (NSC 13128)生产 | 订购Nicotinamide (NSC 13128) | Nicotinamide (NSC 13128)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID